NurExone Biologic publishes Q1 FY2026 MD&A for three months ended March 31, 2026

  • NurExone published its Q1 FY2026 interim MD&A, highlighting a pivot in U.S. manufacturing toward Florida-based collaborations for GMP exosome capacity.
  • Cash and cash equivalents ended March 31, 2026 at US$ 1.51 million; working capital was US$ 943,000.
  • Net loss was US$ 1.77 million; operating loss was US$ 1.76 million; operating cash outflow was US$ 1.24 million.
  • Completed a March 2026 private placement raising gross proceeds of about US$ 642,000 via 1,295,222 units priced at C$ 0.68.
  • Reported batch-to-batch exosome consistency in an independent proteomic analysis, supporting CMC readiness for an ExoPTEN IND submission plan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief on May 31, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.